Metazero Xr (Metoprolol Succinate)

Metoprolol succinate selectively blocks β1‑adrenergic receptors in the heart, slowing the heart rate, decreasing the force of contraction, and lowering renin release. These actions reduce cardiac output and peripheral resistance, which together lower blood pressure and lessen the heart’s oxygen demand.

The appropriate dose of Metazero Xr is determined by the prescribing clinician based on the patient’s specific condition, response, and tolerance. Dosage may be adjusted over time, and patients should follow the exact regimen provided by their healthcare professional.

Safety of metoprolol succinate in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Patients should discuss their individual situation with a qualified clinician.

To request Metazero Xr, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metazero Xr (metoprolol succinate) is a long‑acting, selective β1‑blocker, offering once‑daily dosing and steady plasma levels. Compared with non‑selective beta‑blockers, it has fewer respiratory side effects, and its extended‑release formulation may improve adherence versus immediate‑release alternatives.

Metazero Xr should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Metazero Xr is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed to maintain its extended‑release properties.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible individuals, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, swelling, or difficulty breathing.

Metazero Xr is contraindicated in patients with known hypersensitivity to metoprolol or other beta‑blockers, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, cardiogenic shock, or overt heart failure decompensation. Clinicians should also avoid use in patients with uncontrolled asthma or severe peripheral vascular disease.